Please use this identifier to cite or link to this item: https://doi.org/10.1385/MO:22:3:303
DC FieldValue
dc.titleLiver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: A multicenter phase II study by the cancer therapeutic research group
dc.contributor.authorHo, W.M.
dc.contributor.authorMa, B.
dc.contributor.authorMok, T.
dc.contributor.authorYeo, W.
dc.contributor.authorLai, P.
dc.contributor.authorLim, R.
dc.contributor.authorKoh, J.
dc.contributor.authorWong, Y.Y.
dc.contributor.authorKing, A.
dc.contributor.authorLeow, C.K.
dc.contributor.authorChan, A.T.C.
dc.date.accessioned2016-11-28T10:16:52Z
dc.date.available2016-11-28T10:16:52Z
dc.date.issued2005-09
dc.identifier.citationHo, W.M., Ma, B., Mok, T., Yeo, W., Lai, P., Lim, R., Koh, J., Wong, Y.Y., King, A., Leow, C.K., Chan, A.T.C. (2005-09). Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: A multicenter phase II study by the cancer therapeutic research group. Medical Oncology 22 (3) : 303-312. ScholarBank@NUS Repository. https://doi.org/10.1385/MO:22:3:303
dc.identifier.issn13570560
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/131156
dc.description.abstractThe main objectives of this study were to assess the use of irinotecan, 5-fluorouracil (5-FU), and leucovorin (FA) as neoadjuvant chemotherapy for patients with unresectable colorectal liver metastases and to determine the response rate and proportion of patients that could be downstaged to resectable tumors. Forty patients were treated with irinotecan (180 mg/m2 over 30 min) on d 1, FA (200 mg/m2 over 30 min) followed by 5-FU (400 mg/m2 bolus and continuous infusion of 600 mg/m2 over 22 h) on d 1 and 2 every 2 wk. The overall response rate was 55% (95% CI: 39.5-70.4%). The progression-free survival was 12.1 mo (95% CI: 11.4-14.8 mo). The median overall survival was 20 mo (95% CI: 17.7-26.6 mo). Four patients (10%) have undergone liver resection after a median of eight cycles. Those patients remained alive with a median follow up period of 33 mo. The principal grade 3-4 toxicity was neutropenia in 20 patients (50%). We conclude that the regimen of irinotecan/5-FU/FA was highly active in patients with colorectal cancer and liver metastases with limited toxicity. In a subgroup of patients with initial inoperable liver metastases, this regimen was able to downstage the disease to an operable stage. © Copyright 2005 by Humana Press Inc. All rights of any nature whatsoever reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1385/MO:22:3:303
dc.sourceScopus
dc.subject5-fluorouracil (5-FU)
dc.subjectColorectal cancer (CRC)
dc.subjectFolinic acid (FA), operability
dc.subjectIrinotecan
dc.subjectLiver metastases
dc.typeArticle
dc.contributor.departmentSURGERY
dc.description.doi10.1385/MO:22:3:303
dc.description.sourcetitleMedical Oncology
dc.description.volume22
dc.description.issue3
dc.description.page303-312
dc.description.codenMONCE
dc.identifier.isiut000231533600010
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

54
checked on Jan 30, 2023

WEB OF SCIENCETM
Citations

44
checked on Jan 30, 2023

Page view(s)

183
checked on Feb 2, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.